文献速递临床试验与 GCP基础与转化研究

镰状细胞病儿童叶酸补充研究:双盲随机交叉试验方案

Folic acid supplementation in children with sickle cell disease: study protocol for a double-blind randomized cross-over trial.
PubMed 文献 · Trials · 2020-06-29

本研究为双盲随机交叉试验,纳入36例2-19岁镰状细胞病儿童,随机接受1 mg/d叶酸或安慰剂12周,洗脱12周后交换治疗,比较红细胞叶酸浓度(主要结局)和未代谢叶酸(次要结局)等指标,以评估高剂量叶酸补充的有效性及代谢变化。

要点

  • 评估1 mg/d叶酸与安慰剂对镰状细胞病儿童红细胞叶酸浓度的影响。
  • 同时检测未代谢叶酸等代谢指标及临床结局。
  • 采用双盲随机交叉设计,洗脱期12周。

核心结论

  • 该试验将评估高剂量叶酸补充对镰状细胞病儿童的有效性及叶酸代谢改变。

研究设计与样本

  • 双盲随机对照交叉试验,纳入36例2-19岁镰状细胞病儿童,随机接受1 mg/d叶酸或安慰剂12周,洗脱12周后交换治疗。

关键数值与推荐

  • 主要结局为红细胞叶酸浓度,次要结局为未代谢叶酸(UMFA)。

临床怎么用

  • 试验结果将用于评估当前临床实践中1-5 mg/d叶酸补充推荐是否适用于镰状细胞病儿童。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sickle cell disease (SCD) is a genetic disorder which causes dysfunctional red blood cells (RBC) and is thought to increase requirements for folate, an essential B vitamin, due to increased RBC production and turnover in the disease. High-dose supplementation with 1-5 mg/d folic acid, synthetic folate, has been the standard recommendation for children with SCD. There is concern about whether children with SCD need such high doses of folic acid, following mandatory folic acid fortification of enriched grains in Canada, and advancements in medical therapies which extend the average lifespan of RBCs. In animal and human studies, high folic acid intakes (1 mg/d) have been associated with accelerated growth of some cancers, and the biological effects of circulating unmetabolized folic acid (UMFA), which can occur with doses of folic acid ≥ 0.2 mg/d, are not fully understood. The objective of this study is to determine efficacy of, and alterations in folate metabolism from high-dose folic acid in children with SCD during periods of folic acid supplementation versus no supplementation. METHODS: In this double-blind randomized controlled cross-over trial, children with SCD (n = 36, aged 2-19 years) will be randomized to either receive 1 mg/d folic acid, the current standard of care, or a placebo for 12 weeks. After a 12-week washout period, treatments will be reversed. Total folate concentrations (serum and RBC), different folate forms (including UMFA), folate-related metabolites, and clinical outcomes will be measured at baseline and after treatment periods. The sum of the values measured in the two periods will be calculated for each subject and compared across the two sequence groups by means of a test for independent samples for the primary (RBC folate concentrations) and secondary (UMFA) outcomes. Dietary intake will be measured at the beginning of each study period. DISCUSSION: As the first rigorously designed clinical trial in children with SCD, this trial will inform and assess current clinical practice, with the ultimate goal of improving nutritional status of children with SCD. TRIAL REGISTRATION: ClinicalTrials.gov NCT04011345 . Registered on July 8, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Williams BA, McCartney H, Adams E, et al. Folic acid supplementation in children with sickle cell disease: study protocol for a double-blind randomized cross-over trial. Trials. 2020. PMID: 32600389. doi:10.1186/s13063-020-04540-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。